Ideally, all systemic lupus erythematosus (SLE) patients should be reviewed by a specialist. Early referral to a rheu matologist has been associated with faster treatment modification and better outcomes. However, primary care doctors are the first point of care for new SLE patients or those presenting with a new complication. Moreover, given the shortage of rheumatologists in South Africa (SA) and elsewhere in Africa, primary care clinicians and general physicians are often faced with sick SLE patients and are required to make rapid therapeutic decisions. This review summarises current evidence for the treatment of SLE and its complications. We prepared this review after a PubMed search using the words 'systemic lupus erythematosus' and 'therapy' .
patients 15 years after diagnosis. [3] The damage is propor tional to both the cumulative dose of CS and the average daily dose, and even low doses (<7.5 mg daily) are associated with a risk of cataracts, cardiovascular (CV) disease and osteoporosis. [4] The best practice is to prescribe CS only to patients with severe organ involvement at the lowest effective dose for the shortest duration of time possible. A recent study demonstrated that moderate doses (≤30 mg/day) of CS for severe nonrenal SLE were as effective and associated with fewer adverse effects than high doses. [5] Another study demonstrated that after pulse methylprednisolone, oral CS may be omitted from an induction immunosuppressive regimen for nephritis. [6] An understanding of currently available immunosuppressant drugs such as methotrexate (MTX), azathioprine (AZA), cyclophosphamide (CYC) and mycophenylate mofetil (MMF) is vital in a steroidsparing approach (Table 2 ).
Monitoring SLE patients
For patients with inactive disease, 4monthly visits should include a clinical examination, blood pressure measurement, urine dipstick test, full blood count, and liver transaminase for those using potentially hepatotoxic medication. Other serum markers of active disease such as complement (C3 and C4), doublestranded DNA (dsDNA), and Creactive protein may be useful for followup, but do not accurately predict flares. An annual lipogram, creatinine measurement, and HIV test are recommended. Screening for antiphospholipid antibodies at diagnosis is useful. As therapy of acute SLE improves, patients live longer. Therefore, comorbidities of the disease or complications of therapy have emerged as important causes of morbidity and mortality. Preventive and therapeutic strategies are summarised in Table 3 .
Infections
The combination of inherent immune dysfunction and immuno suppressant therapy, in particular CS, puts SLE patients at high risk of communityacquired and opportunistic infections. [7] These infections contribute significantly to the hospitalisation and mortality of SLE patients, and need to be distinguished from an SLE flare, bearing in mind that infections may also occur together with flares. Vaccination, vigilance, easy access to well informed clinicians and prompt antibiotic therapy are important measures. Moreover, SLE patients are at higher risk of pulmonary and extrapulmonary tuberculosis (TB); this risk is related to CS use, lymphopenia, and lupus disease itself. [8] Clinicians need to consider the possibility of TB in any ill SLE patient.
Atherosclerosis
Patients with SLE have a 2 5fold increased risk of cardiac, cerebral or peripheral ar terial atherosclerosic events, and CV events are the leading cause of mortality in SLE. [9] Traditional Framingham CV risk factors do not fully explain the extent of the risk, as inflam matory and prothrombotic mechanisms underlie this premature atherosclerosis. Encouragingly, the CV risk may be reduced by regular exercise, statin therapy and possibly lowdose aspirin for any patient with ≥1 traditional risk factors for atherosclerotic disease, or with antiphospholipid antibodies. [10, 11] 
Antiphospholipid syndrome
Antiphospholipid antibodies are commonly encountered in SLE patients and are associated with a 50% risk of thrombo embolism. [12] Despite the lack of evidence for primary prevention of thombosis and pregnancy loss, experts recommend low dose aspirin and AMs for SLE patients with anti phospholipid antibodies, especially when other risk factors for thrombosis coexist. [13] With regard to secondary prevention, patients with previous venous thrombosis, moderateintensity warfarin therapy (target international normalised ratio (INR) 2.0 3.0) is appropriate. In the case of previous arterial thrombosis or stroke, highintensity warfarin therapy (target INR 3.1 4.0) is preferable. Very recently it has been shown that nonvitamin K antagonist oral anticoagulants may be safe and effective alternatives to warfarin in antiphospholipid patients with previous venous events. [14] 
Management of major organ involvement Nephritis
Nephritis is one of the most severe mani festations of SLE and one of the major predictors of poor prognosis. A urine dipstick test at each assessment is mandatory. An abnormal test warrants urine microscopy and a urine protein:creatinine ratio. Renal biopsy is indicated in any patient with active urinary sediment or significant proteinuria.
Treatment of lupus nephritis consists of induction followed by a maintenance phase. Induction therapy for proliferative or membranous nephritis with CS combined with an immunosuppressive agent prevents progression to endstage renal disease. CS may be given as pulse methylprednisolone, or as oral CS, tapered over a few weeks to the lowest effective oral dose. [15] There is a high rate of relapse in patients treated with CS alone. [16] The current firstline choice of immunosuppressant is either CYC or MMF. Highdose, intermittent CYC ('the NIH regimen') or lower dose CYC (the EuroLupus regimen) are acceptable approaches, but in patients with severe disease (nephroticrange proteinuria or renal impairment), and in black or mixedancestry patients, the highdose CYC regimen may be preferable. [17] In young females who have not yet completed their families, MMF may be more suitable than CYC. Rituximab or tacrolimus may be useful in cases refractory or intolerant to conven tional therapies. [18, 19] Importantly, early response to therapy predicts longterm renal outcome; therefore, patients with ongoing proteinuria and active urinary sediment at 6 months should be switched to another regimen. [20] Maintenance therapy should be with AZA or MMF for at least 3 years. Relapses are common, and diligent followup is important.
Neuropsychiatric lupus
Neuropsychiatric lupus (NPSLE) is another of the serious manifestations of SLE, and may be secondary to sepsis, metabolic abnormalities, and drug sideeffects, or may be directly related to the SLE (primary NPSLE). Nineteen NPSLE syndromes have been recognised, including seizures, psychosis, stroke, mood disorder, transverse myelitis, cognitive dysfunction, and peripheral neuropathy. The pathogenesis of primary NPSLE is thought to be either (i) immunemediated inflammation or demyelination, and/ or (ii) ischaemic injury due to microangiopathy, thrombosis or emboli, frequently associated with antiphospholipid antibodies. Magnetic resonance imaging (MRI) is usually considered to be the gold standard imaging modality in the evaluation of cerebral lesions in patients with SLE, and a recent study showed that diffuse cortical MRI lesions are likely to be associated with immunemediated inflammation, whereas focal white or grey matter hyperintensities are more likely to be ischaemic or related to vasculitis. [21] Inflammatory syndromes are best managed with immunosuppressive therapy, whereas ischaemic events may require anticoagulation.
Moreover, SLE is a wellknown risk factor for depres sion, anxiety and fatigue, which tend to be poorly addressed by physicians. Several studies highlight the impor tance of focusing on and addressing individual patient's psychosocial situations.
Heart
Myocarditis (best detected by MRI) and endocarditis are uncommon but serious complications of SLE, while pericarditis may lead to tamponade and is treated with moderatedose CS and AMs. Refractory disease may respond to AZA, MMF, MTX, belimumab or rituximab.
Cytopenias
Anaemia is common in SLE, and may be due to anaemia of chronic disease, iron deficiency, chronic renal insufficiency or autoimmune haemolytic anaemia (AIHA). AIHA must be treated with oral CS or pulse methylprednisolone, and if refractory may require AZA, CYC, MMF or splenectomy.
Immune thrombocytopenia is an independent risk factor for increased mortality in SLE and should be treated with oral CS or pulse methylprednisolone and AMs. In refractory cases, AZA, cyclosporin, intravenous immunoglobulins (IVIGs), MMF, danazol, CYC or splenectomy may be considered.
Thrombotic thrombocytopenic purpura is a rare but life threatening complication of SLE, characterised by severe thrombo cytopenia, microangiopathic haemolytic anaemia, neurological abnormalities, renal insufficiency and fever with fragmented red blood cells on peripheral blood smear. Plasmapheresis is the mainstay of treatment. Other therapies that have been used include highdose CS, CYC, IVIGs and rituximab.
Skin
Acute and chronic skin lesions are very common, affecting 70 85% of patients, and are frequently of great concern to patients. Prompt therapy is necessary to avoid irreversible scarring, alopecia and depigmentation. All SLE patients should wear daily sunscreen (SPF ≥50). Treatment with AMs and topical CS is very effective. Small studies support the use of MTX, AZA, MMF, retinoids and dapsone for refractory cases. [22] 
Arthritis
Arthritis is a common presenting feature of SLE, and may be underrecognised. A recent MRI study showed a high incidence of subclinical hand and wrist arthritis, with erosions not infrequently seen, which may offer an explanation for the high prevalence of arthralgias in SLE patients. [23] Arthritis in SLE should be treated with AMs, shortterm nonsteroidal antiinflammatory drugs, and lowdose (<10 mg) CS. Patients with ongoing arthritis may benefit from MTX.
Pregnancy
Because SLE is frequently a disease affecting women of childbearing age, fertility and pregnancy may be important issues. Patients should be reassured that successful fullterm pregnancies are possible, and that the best time to conceive is once SLE is inactive. Pregnancy, particularly if it occurs in a patient with active SLE, may cause flares, especially worsening of lupus nephritis. CYC may affect fertility, and the risks are greatest if high cumulative doses are used (>15 g) and when given to women >30 years of age. Antiphospholipid antibodies are a risk factor for miscarriage, stillbirth, preeclampsia and premature delivery. Fetal congenital heart block is associated with antiRo/SSA or antiLa/SSB antibodies.
In pregnant SLE patients, AMs prevent flares and reduce the occurrence of congenital heart block. The incidence of fetal abnormalities is very low (although most studies have evaluated HQ, which may be safer than CQ). Hence, most experts believe that, after a detailed conversation with each patient, AMs should be continued during pregnancy and lactation. Glucocorticoids, AZA, and lowdose aspirin are considered safe in pregnancy, whereas MMF, CYC and MTX are contraindicated. Lowmolecularweight heparin with aspirin is indicated in patients with antiphospholipid antibodies and previous miscarriage to reduce the risk of pregnancy loss. [24] Contraception and hormone replacement therapy Because of concerns of flares precipitated by exogenous oestrogens, women with SLE have traditionally been counselled against the use of hormonal oral contraceptives (OCs). Recent randomised controlled trials, however, have confirmed the safety of OCs in SLE. [25] Because of the risk of thrombosis (both venous thrombosis with thromboembolism and myocardial infarction), OCs should be avoided in patients with antiphospholipid antibodies. Long term hormone replacement therapy, although seemingly desirable in patients with premature menopause or osteoporosis, should be avoided because of the risk of mild to moderate flares and thrombosis.
Newer therapies
Improved understanding of the pathogenesis of SLE has paved the way for the development of new biologic agents. Rituximab, a humanised monoclo nal antibody targeting CD20 recep tors on B lymphocytes, is useful in refractory nephritis, severe haematological disease and NPSLE. Belimumab inhibits Blymphocyte stimulator and has recently been approved in the USA for mild to moderate disease. Several novel agents are currently being evaluated for safety and efficacy in lupus.
